Anti-Parkinson Drugs Market Report 2026

The anti-parkinson drugs market size has grown steadily in recent years. It will grow from $10.96 billion in 2025 to $11.46 billion in 2026 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to aging population growth, increased parkinson’s disease diagnosis, long-standing use of levodopa, improved neurological care, chronic disease management needs.

The anti-parkinson drugs market size is expected to see strong growth in the next few years. It will grow to $14.28 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to rising neurodegenerative disorders, innovation in neuroprotective drugs, expansion of transdermal therapies, increased healthcare access, focus on quality of life improvement. Major trends in the forecast period include rising demand for dopaminergic therapies, growing use of extended-release formulations, increasing focus on symptom management, expansion of combination drug therapies, improved drug delivery technologies.

The increasing incidence of mental health disorders is expected to drive the growth of the mental wellness market in the coming years. Mental health disorders are clinically significant impairments in a person's cognition, emotional regulation, or behavior. The rising prevalence of mental disorders is attributed to greater exposure to chronic stress and adverse life experiences, which overwhelm individual coping mechanisms and trigger psychological dysfunction. The growing incidence of mental disorders also supports the expansion of the anti-Parkinson drugs market, as these drugs help mitigate and treat mental health conditions. For example, in October 2025, according to the Institute for Health Metrics and Evaluation, a US-based health research organization, 15% of the global population experienced mental disorders in 2023, and 17% of total years lived with disability worldwide were attributed to mental disorders in the same year. Therefore, the high prevalence of mental disorders is fueling the growth of the anti-Parkinson drugs market.

Major companies operating in the anti-Parkinson drugs market are concentrating on developing advanced therapeutic approaches targeting motor fluctuations and dyskinesia to improve symptom management and reduce side effects. Motor fluctuations and dyskinesia frequently complicate Parkinson's disease treatment, impacting patient quality of life. For example, in January 2024, AbbVie Inc., a US-based pharmaceutical company, introduced PRODUODOPA. PRODUODOPA (foslevodopa/foscarbidopa) is the first subcutaneous 24-hour infusion therapy for advanced Parkinson's disease, designed to address severe motor fluctuations and dyskinesia when other therapies are insufficient. It provides a continuous delivery of levodopa, potentially increasing 'on' time and enhancing symptom control.

In October 2023, AbbVie Inc., a pharmaceutical company based in the US, acquired Mitokinin for $110 million. Through this acquisition, AbbVie Inc. aims to enhance its neuroscience pipeline and offer a new treatment option for patients with Parkinson’s disease. Mitokinin is a US-based biotechnology company that develops treatments for Parkinson’s disease (PD).

Major companies operating in the anti-parkinson drugs market are GlaxoSmithKline plc, Pfizer Inc., Novartis AG, F. Hoffmann-La Roche AG, UCB S.A, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Mylan NV, C.H. Boehringer Sohn AG & Co. KG, Orion Pharma Ltd., Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., US WorldMeds LLC, Zydus Lifesciences Limited, Chemical Industrial & Pharmaceutical Laboratories Ltd., Strides Shasun Ltd., Upsher-Smith Laboratories LLC, H. Lundbeck A/S, Vertical Pharmaceuticals LLC, Zambon SPA, Valeant Pharmaceuticals International Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc.

North America was the largest region in the anti-Parkinson drugs market in 2025. Middle East is expected to be the fastest-growing region in the anti-parkinson drugs market during the forecast period. The regions covered in the anti-parkinson drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anti-parkinson drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the cost of imported neurological drug ingredients, including active pharmaceutical ingredients and formulation intermediates used in therapy manufacturing. These effects are most evident in Europe and Asia, where many producers depend on cross border sourcing for critical inputs. Rising tariff related costs have placed pressure on manufacturing expenses and pricing of essential neurological medications. This has influenced procurement strategies for hospitals and public health systems. However, tariffs are also promoting local production of essential neurological medications, regional supplier development, and improved supply security over the long term.

The anti-parkinson drugs market research report is one of a series of new reports that provides anti-parkinson drugs market statistics, including anti-parkinson drugs industry global market size, regional shares, competitors with a anti-parkinson drugs market share, detailed anti-parkinson drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-parkinson drugs industry. This anti-parkinson drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anti-Parkinson drugs refer to medications primarily used for the treatment of Parkinson's disease. They are not classified as psychiatric medications and, therefore, cannot be legally prescribed for mental health conditions. However, a doctor or psychiatrist may suggest using one of these medications alongside an antipsychotic to help reduce certain side effects associated with the antipsychotic.

The primary classes of anti-Parkinson drugs include levodopa/carbidopa, dopamine receptor agonists, monoamine oxidase type B (MAO-B) inhibitors, catechol-O-methyltransferase (COMT) inhibitors, anticholinergics, and other medications. Catechol-O-methyltransferase (COMT) inhibitors are used to manage Parkinson’s disease symptoms when combined with carbidopa-levodopa therapy. The main categories of fertility drugs consist of prescription fertility medications and over-the-counter fertility products. These drugs are administered orally, via injection, or through transdermal methods and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The anti-parkinson drugs market consists of sales of catechol-O-methyl transferase [COMT] inhibitors, anticholinergic drugs, and amantadine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.